Neutrophil-to-lymphocyte ratio (NLR) trends and treatment response to programmed death/ligand 1 (PD-1/PD-L1) inhibitors in non-small cell lung cancer (NSCLC). (January 2019) - Yang, H.; Jayaprakash, K. Thippu; Aslam, S.; Jeffs, Y.; Jessop, S.; Mckay, N.; Cawood, H.; Bulusu, V.R.